Getagraph.com logo
NASDAQ Composite: ( -0.07%) 16 686
S&P 500 Futures
(0.10%) 5 332.75 points
Dow Jones Futures
(0.06%) 40 161 points
Nasdaq Futures
(0.16%) 18 664 points
Oil
(0.37%) $80.36
Gas
(0.95%) $2.65
Gold
(1.19%) $2 446.10
Silver
(3.07%) $32.22
Platinum
(0.04%) $1 090.40
USD/EUR
(-0.02%) $0.920
USD/NOK
(-0.02%) $10.67
USD/GBP
(0.09%) $0.788
USD/RUB
(-0.40%) $90.61

Realtime updates for Kiniksa Pharmaceuticals [KNSA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated17 May 2024 @ 16:00
25% discount on Stockinvest.us - Use code: Podcast

-1.69% $ 19.77

SELL 138924 min ago

@ $19.84

Issued: 13 Feb 2024 @ 15:47

Return: -0.35%

Previous signal: Feb 12 - 13:31

Previous signal: Buy

Return: -4.34 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide...

Stats
Today's Volume 247 456
Average Volume 383 552
Market Cap 1.40B
EPS $0 ( 2024-05-07 )
Next earnings date ( $-0.0900 ) 2024-07-23
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 152.08
ATR14 $0.0130 (0.07%)
Insider Trading
Date Person Action Amount type
2024-05-03 Levy Richard S Buy 747 Class A Common Share
2024-05-03 Levy Richard S Buy 747 Restricted Share Units
2024-05-03 Levy Richard S Sell 747 Restricted Share Units
2024-04-26 Ragosa Mark Buy 991 Class A Common Share
2024-04-26 Ragosa Mark Sell 509 Class A Common Share
INSIDER POWER
23.36
Last 100 transactions
Buy: 555 036 | Sell: 364 871

Volume Correlation

Long: -0.31 (neutral)
Short: 0.79 (moderate)
Signal:(54.564) Neutral

Kiniksa Pharmaceuticals Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kiniksa Pharmaceuticals Correlation - Currency/Commodity

The country flag -0.05
( neutral )
The country flag 0.16
( neutral )
The country flag 0.00
( neutral )
The country flag 0.14
( neutral )
The country flag -0.53
( weak negative )
The country flag 0.36
( neutral )

Kiniksa Pharmaceuticals Financials

Annual 2023
Revenue: $270.26M
Gross Profit: $179.22M (66.31 %)
EPS: $0.200
FY 2023
Revenue: $270.26M
Gross Profit: $179.22M (66.31 %)
EPS: $0.200
FY 2022
Revenue: $220.18M
Gross Profit: $173.21M (78.67 %)
EPS: $2.64
FY 2021
Revenue: $38.54M
Gross Profit: $29.44M (76.39 %)
EPS: $-2.30

Financial Reports:

No articles found.

Kiniksa Pharmaceuticals Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators